Summary
Vertex Pharmaceuticals reported a return to profitability in the six months ended June 30, 2017, with net income attributable to Vertex of $265.8 million, a significant improvement from a net loss of $106.2 million in the same period of 2016. This turnaround was largely driven by a substantial increase in total revenues, which rose to $1.26 billion from $830 million, primarily boosted by a $230 million upfront payment from Merck KGaA for an oncology collaboration and increased product revenues from its key cystic fibrosis (CF) drugs, ORKAMBI and KALYDECO. The company continues to invest heavily in research and development, particularly in its next-generation CFTR corrector compounds for CF, with promising early-stage clinical trial data. The acquisition of CTP-656 from Concert Pharmaceuticals for $160 million highlights Vertex's commitment to expanding its CF pipeline. While the company faces ongoing challenges in securing ex-U.S. reimbursement for ORKAMBI, its overall financial performance shows a positive trajectory, supported by strong product sales and strategic collaborations.
Financial Highlights
50 data points| Revenue | $544.13M |
| Cost of Revenue | $71.20M |
| Gross Profit | $472.93M |
| R&D Expenses | $289.45M |
| SG&A Expenses | $127.25M |
| Operating Expenses | $491.43M |
| Operating Income | $52.71M |
| Net Income | $18.00M |
| EPS (Basic) | $0.07 |
| EPS (Diluted) | $0.07 |
| Shares Outstanding (Basic) | 247.52M |
| Shares Outstanding (Diluted) | 251.63M |
Key Highlights
- 1Vertex Pharmaceuticals reported a net income of $265.8 million for the six months ended June 30, 2017, compared to a net loss of $106.2 million in the prior year period.
- 2Total revenues increased significantly by 52% to $1.26 billion for the first half of 2017, driven by a $230 million upfront payment from a Merck KGaA collaboration and strong product sales.
- 3Product revenues from ORKAMBI and KALYDECO increased by 21% to $994.6 million for the first half of 2017, demonstrating continued growth in Vertex's core CF franchise.
- 4The company submitted New Drug and Marketing Authorization Applications for tezacaftor in combination with ivacaftor, a key potential new treatment for CF.
- 5Vertex is advancing its next-generation CFTR corrector compounds in triple combination regimens for CF, showing promising early clinical trial data for VX-152, VX-440, and VX-659.
- 6The company acquired CTP-656, an investigational CFTR potentiator, from Concert Pharmaceuticals for $160 million in July 2017 to further strengthen its CF pipeline.
- 7Operating expenses increased by 11% to $935.3 million for the first half of 2017, primarily due to higher R&D and SG&A expenses, reflecting ongoing investments in drug development and commercial support.